Filopodia powered by class X myosin promote fusion of mammalian myoblasts

  1. David W Hammers
  2. Cora C Hart
  3. Michael K Matheny
  4. Ernest G Heimsath
  5. Young il Lee
  6. John A Hammer III
  7. Richard E Cheney
  8. H Lee Sweeney  Is a corresponding author
  1. University of Florida, United States
  2. University of North Carolina, United States
  3. National Heart, Lung and Blood Institute, United States
  4. University of North Carolina School of Medicine, United States

Abstract

Skeletal muscle fibers are multinucleated cellular giants formed by the fusion of mononuclear myoblasts. Several molecules involved in myoblast fusion have been discovered, and finger-like projections coincident with myoblast fusion have also been implicated in the fusion process. The role of these cellular projections in muscle cell fusion was investigated herein. We demonstrate that these projections are filopodia generated by class X myosin (Myo10), an unconventional myosin motor protein specialized for filopodia. We further show that Myo10 is highly expressed by differentiating myoblasts, and Myo10 ablation inhibits both filopodia formation and myoblast fusion in vitro. In vivo, Myo10 labels regenerating muscle fibers associated with Duchenne muscular dystrophy and acute muscle injury. In mice, conditional loss of Myo10 from muscle-resident stem cells, known as satellite cells, severely impairs postnatal muscle regeneration. Furthermore, the muscle fusion proteins Myomaker and Myomixer are detected in myoblast filopodia. These data demonstrate that Myo10-driven filopodia facilitate multi-nucleated mammalian muscle formation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided

Article and author information

Author details

  1. David W Hammers

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2129-4047
  2. Cora C Hart

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Michael K Matheny

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ernest G Heimsath

    Cell Biology & Physiology, University of North Carolina, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Young il Lee

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. John A Hammer III

    Cell Biology and Physiology Center, National Heart, Lung and Blood Institute, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2496-5179
  7. Richard E Cheney

    Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6565-7888
  8. H Lee Sweeney

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    For correspondence
    lsweeney@ufl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6290-8853

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR075637)

  • H Lee Sweeney

National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54-AR-052646)

  • H Lee Sweeney

Fondation Leducq (13CVD04)

  • H Lee Sweeney

Muscular Dystrophy Association (MDA549004)

  • David W Hammers

National Institute of General Medical Sciences (R01-GM134531)

  • Richard E Cheney

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Florida. Protocol #201910602.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,626
    views
  • 272
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David W Hammers
  2. Cora C Hart
  3. Michael K Matheny
  4. Ernest G Heimsath
  5. Young il Lee
  6. John A Hammer III
  7. Richard E Cheney
  8. H Lee Sweeney
(2021)
Filopodia powered by class X myosin promote fusion of mammalian myoblasts
eLife 10:e72419.
https://doi.org/10.7554/eLife.72419

Share this article

https://doi.org/10.7554/eLife.72419

Further reading

    1. Cell Biology
    2. Medicine
    Shuo He, Lei Huang ... Jinlong He
    Research Article

    Disturbed shear stress-induced endothelial atherogenic responses are pivotal in the initiation and progression of atherosclerosis, contributing to the uneven distribution of atherosclerotic lesions. This study investigates the role of Aff3ir-ORF2, a novel nested gene variant, in disturbed flow-induced endothelial cell activation and atherosclerosis. We demonstrate that disturbed shear stress significantly reduces Aff3ir-ORF2 expression in athero-prone regions. Using three distinct mouse models with manipulated Aff3ir-ORF2 expression, we demonstrate that Aff3ir-ORF2 exerts potent anti-inflammatory and anti-atherosclerotic effects in Apoe-/- mice. RNA sequencing revealed that interferon regulatory factor 5 (Irf5), a key regulator of inflammatory processes, mediates inflammatory responses associated with Aff3ir-ORF2 deficiency. Aff3ir-ORF2 interacts with Irf5, promoting its retention in the cytoplasm, thereby inhibiting the Irf5-dependent inflammatory pathways. Notably, Irf5 knockdown in Aff3ir-ORF2 deficient mice almost completely rescues the aggravated atherosclerotic phenotype. Moreover, endothelial-specific Aff3ir-ORF2 supplementation using the CRISPR/Cas9 system significantly ameliorated endothelial activation and atherosclerosis. These findings elucidate a novel role for Aff3ir-ORF2 in mitigating endothelial inflammation and atherosclerosis by acting as an inhibitor of Irf5, highlighting its potential as a valuable therapeutic approach for treating atherosclerosis.

    1. Cell Biology
    2. Genetics and Genomics
    Róża K Przanowska, Yuechuan Chen ... Anindya Dutta
    Research Article

    The six-subunit ORC is essential for the initiation of DNA replication in eukaryotes. Cancer cell lines in culture can survive and replicate DNA replication after genetic inactivation of individual ORC subunits, ORC1, ORC2, or ORC5. In primary cells, ORC1 was dispensable in the mouse liver for endo-reduplication, but this could be explained by the ORC1 homolog, CDC6, substituting for ORC1 to restore functional ORC. Here, we have created mice with a conditional deletion of ORC2, which does not have a homolog. Although mouse embryo fibroblasts require ORC2 for proliferation, mouse hepatocytes synthesize DNA in cell culture and endo-reduplicate in vivo without ORC2. Mouse livers endo-reduplicate after simultaneous deletion of ORC1 and ORC2 both during normal development and after partial hepatectomy. Since endo-reduplication initiates DNA synthesis like normal S phase replication these results unequivocally indicate that primary cells, like cancer cell lines, can load MCM2-7 and initiate replication without ORC.